Neurobiology of Disease

Journal

Publication Venue For

  • Human and rodent temporal lobe epilepsy is characterized by changes in O-GlcNAc homeostasis that can be reversed to dampen epileptiform activity.  124:531-543. 2019
  • Reduction of microglial progranulin does not exacerbate pathology or behavioral deficits in neuronal progranulin-insufficient mice.  124:152-162. 2019
  • Alpha-synuclein deregulates the expression of COL4A2 and impairs ER-Golgi function.  119:121-135. 2018
  • Corrigendum to “Deficits in synaptic function occur at medial perforant path-dentate granule cell synapses prior to Schaffer collateral-CA1 pyramidal cell synapses in the novel TgF344-Alzheimer's Disease Rat Model” [Neurobiology of Disease Volume 110, February 2018, Pages 166–179] (S0969996117302759) (10.1016/j.nbd.2017.11.014)).  118:177-178. 2018
  • Behavioral and SCN neurophysiological disruption in the Tg-SwDI mouse model of Alzheimer's disease.  114:194-200. 2018
  • Muscle microRNA signatures as biomarkers of disease progression in amyotrophic lateral sclerosis.  114:85-94. 2018
  • Deficits in synaptic function occur at medial perforant path-dentate granule cell synapses prior to Schaffer collateral-CA1 pyramidal cell synapses in the novel TgF344-Alzheimer's Disease Rat Model.  110:166-179. 2018
  • The lysosomal enzyme alpha-Galactosidase A is deficient in Parkinson's disease brain in association with the pathologic accumulation of alpha-synuclein.  110:68-81. 2018
  • Effects of α-synuclein on axonal transport.  105:321-327. 2017
  • α-Synuclein fibril-induced inclusion spread in rats and mice correlates with dopaminergic Neurodegeneration.  105:84-98. 2017
  • Dysregulation of BET proteins in levodopa-induced dyskinesia.  102:125-132. 2017
  • Fbxl18 targets LRRK2 for proteasomal degradation and attenuates cell toxicity.  98:122-136. 2017
  • The neurobiology of HIV and its impact on cognitive reserve: A review of cognitive interventions for an aging population.  92:144-156. 2016
  • An altered peripheral IL6 response in major depressive disorder.  89:46-54. 2016
  • Astrogliopathology in neurological, neurodevelopmental and psychiatric disorders.  85:254-261. 2016
  • Increased 14-3-3 phosphorylation observed in Parkinson's disease reduces neuroprotective potential of 14-3-3 proteins.  79:1-13. 2015
  • Hyperactivity and cortical disinhibition in mice with restricted expression of mutant huntingtin to parvalbumin-positive cells.  62:160-171. 2014
  • Phenotypic characterization of recessive gene knockout rat models of Parkinson's disease.  70:190-203. 2014
  • Surprising behavioral and neurochemical enhancements in mice with combined mutations linked to Parkinson's disease.  62:113-123. 2014
  • Enhanced Ca2+-dependent glutamate release from astrocytes of the BACHD Huntington's disease mouse model.  58:192-199. 2013
  • Neurodevelopmental impairment following neonatal hyperoxia in the mouse.  50:69-75. 2013
  • Preferential inactivation of SCN1A in parvalbumin interneurons increases seizure susceptibility.  49:211-220. 2013
  • Cholinergic dysregulation produced by selective inactivation of the dystonia-associated protein torsinA.  47:416-427. 2012
  • Update on the pathology of dystonia.  42:148-151. 2011
  • Human cytomegalovirus UL97 kinase prevents the deposition of mutant protein aggregates in cellular models of Huntington's disease and Ataxia.  41:11-22. 2011
  • Mice with altered serotonin 2C receptor RNA editing display characteristics of Prader-Willi syndrome.  39:169-180. 2010
  • Dopamine D2 receptor dysfunction is rescued by adenosine A2A receptor antagonism in a model of DYT1 dystonia.  38:434-445. 2010
  • Neuroinflammation in Parkinson's disease: Its role in neuronal death and implications for therapeutic intervention.  37:510-518. 2010
  • VPS41, a protein involved in lysosomal trafficking, is protective in Caenorhabditis elegans and mammalian cellular models of Parkinson's disease.  37:330-338. 2010
  • Dendritic spine pathologies in hippocampal pyramidal neurons from Rett syndrome brain and after expression of Rett-associated MECP2 mutations.  35:219-233. 2009
  • Focal cerebral ischemia in rats alters APP processing and expression of Aβ peptide degrading enzymes in the thalamus.  35:103-113. 2009
  • Oral apolipoprotein A-I mimetic peptide improves cognitive function and reduces amyloid burden in a mouse model of Alzheimer's disease.  34:525-534. 2009
  • Bdnf overexpression in hippocampal neurons prevents dendritic atrophy caused by Rett-associated MECP2 mutations.  34:199-211. 2009
  • Impaired striatal D2 receptor function leads to enhanced GABA transmission in a mouse model of DYT1 dystonia.  34:133-145. 2009
  • DHA and cholesterol containing diets influence Alzheimer-like pathology, cognition and cerebral vasculature in APPswe/PS1dE9 mice.  33:482-498. 2009
  • Decreased glutamate transport enhances excitability in a rat model of cortical dysplasia.  32:254-261. 2008
  • Transcriptional dysregulation in a transgenic model of Parkinson disease.  29:515-528. 2008
  • Changes in cerebral blood volume and amyloid pathology in aged Alzheimer APP/PS1 mice on a docosahexaenoic acid (DHA) diet or cholesterol enriched Typical Western Diet (TWD).  28:16-29. 2007
  • Effects of gender on nigral gene expression and parkinson disease.  26:606-614. 2007
  • Altered responses to dopaminergic D2 receptor activation and N-type calcium currents in striatal cholinergic interneurons in a mouse model of DYT1 dystonia.  24:318-325. 2006
  • Brain-derived neurotrophic factor does not influence age at neurologic onset of Huntington's disease.  24:280-285. 2006
  • Anti-Aβ single-chain antibody delivery via adeno-associated virus for treatment of Alzheimer's disease.  23:502-511. 2006
  • Deposition of mouse amyloid β in human APP/PS1 double and single AD model transgenic mice.  23:653-662. 2006
  • Transcriptional repression and cell death induced by nuclear aggregates of non-polyglutamine protein.  20:656-665. 2005
  • Locomotor activity and evoked dopamine release are reduced in mice overexpressing A30P-mutated human α-synuclein.  20:303-313. 2005
  • Longitudinal observation on CSF Aβ42 levels in young to middle-aged amyloid precursor protein/presenilin-1 doubly transgenic mice.  17:516-523. 2004
  • Erratum: Gender differences in the amount and deposition of amyloidβ in APPswe and PS1 double transgenic mice (Neurobiology of Disease (2003) 14 (318-327) DOI: 10.1016/j.nbd.2003.08.009).  16:290. 2004
  • Normal induction but accelerated decay of LTP in APP + PS1 transgenic mice.  15:188-195. 2004
  • Complex alteration of NMDA receptors in transgenic Huntington's disease mouse brain: Analysis of mRNA and protein expression, plasma membrane association, interacting proteins, and phosphorylation.  14:624-636. 2003
  • DNA microarray analysis of functionally discrete human brain regions reveals divergent transcriptional profiles.  14:240-250. 2003
  • Gender differences in the amount and deposition of amyloidβ in APPswe and PS1 double transgenic mice.  14:318-327. 2003
  • TorsinA protein and neuropathology in early onset generalized dystonia with GAG deletion.  12:11-24. 2003
  • Hippocampal Aβ42 levels correlate with spatial memory deficit in APP and PS1 double transgenic mice.  9:339-347. 2002
  • Cellular distribution of NMDA glutamate receptor subunit mRNAs in the human cerebellum.  4:35-46. 1997
  • Huntington’s disease cag trinucleotide repeats in pathologically confirmed post-mortem brains.  1:159-166. 1994
  • A systematic review of vagus nerve stimulation and its association with inflammation and cognition: A potential treatment for HIV-associated neurocognitive disorders.
  • International Standard Serial Number (issn)

  • 0969-9961
  • Electronic International Standard Serial Number (eissn)

  • 1095-953X